These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 230054)

  • 1. Urinary cyclic AMP and bone histology in Walker carcinosarcoma: evidence of parathyroid hormone-like activity.
    Schmidt-Gayk H; Löhrke H; Fischkal A; Goerttler K; Hofmann F
    Eur J Cancer (1965); 1979 Oct; 15(10):1211-8. PubMed ID: 230054
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypercalcemic activity of Walker carcinosarcoma 256 in the rat].
    Minne H; Ziegler R; Schmitt W; Hilgard P
    Schweiz Med Wochenschr; 1971 Apr; 101(13):481-3. PubMed ID: 5558917
    [No Abstract]   [Full Text] [Related]  

  • 3. Abnormal bone and parathyroid histology in carcinoma patients with pseudohyperparathyroidism.
    Sharp CF; Rude RK; Terry R; Singer FR
    Cancer; 1982 Apr; 49(7):1449-55. PubMed ID: 6277464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma 1.25 (OH)2D and PTH levels and urinary cyclic AMP response to exogenous PTH in PHP during childhood (author's transl)].
    Seino Y; Ishida M; Shimotsuji J; Ishii T; Matsuda S
    Horumon To Rinsho; 1979 Aug; 27(8):879-84. PubMed ID: 226296
    [No Abstract]   [Full Text] [Related]  

  • 5. The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256.
    Minne H; Raue F; Bellwinkel S; Ziegler R
    Acta Endocrinol (Copenh); 1975 Mar; 78(3):613-24. PubMed ID: 1173020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of hypercalcemia in nude mice bearing a human renal carcinoma.
    Strewler GJ; Wronski TJ; Halloran BP; Miller SC; Leung SC; Williams RD; Nissenson RA
    Endocrinology; 1986 Jul; 119(1):303-10. PubMed ID: 3013591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased 1,25-dihydroxycholecalciferol as a cause of abnormal calcium metabolism in sarcoidosis.
    Koide Y; Kugai N; Kimura S; Fujita T; Yamashita N; Hiramoto ; Sukegawa J; Ogata E; Yamashita K
    J Clin Endocrinol Metab; 1981 Mar; 52(3):494-8. PubMed ID: 6257749
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteolytic activity of Walker carcinosarcoma 256 is due to parathyroid hormone-related protein (PTHrP).
    Scharla SH; Minne HW; Lempert UG; Krieg P; Rappel S; Maurer E; Grohe U; Ziegler R
    Horm Metab Res; 1991 Feb; 23(2):66-9. PubMed ID: 1646150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma of Walker-256 carcinosarcoma bearing rats contains parathormone related peptide.
    Torres R; Díaz Diego EM; de la Piedra C; Rapado A
    Horm Metab Res; 1992 May; 24(5):246-7. PubMed ID: 1398467
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of osteolytic substances on the production of osseous metastases from Walker 256 sarcoma in rats.
    Graham WP; Tragus ET; Blakemore WS
    J Surg Oncol; 1974; 6(2):117-21. PubMed ID: 4822896
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypercalcaemia. Management.
    Selby PC; Peacock M; Marshall DH
    Br J Hosp Med; 1984 Mar; 31(3):186, 188, 190 passim. PubMed ID: 6324944
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal lesions associated with the Walker 256 adenocarcinoma in the rat.
    Dinh BL; Brassard A
    Br J Exp Pathol; 1968 Apr; 49(2):145-51. PubMed ID: 4967169
    [No Abstract]   [Full Text] [Related]  

  • 13. Walker 256/S carcinosarcoma causes osteoporosis-like changes through ectopical secretion of luteinizing hormone-releasing hormone.
    Waki Y; Nomura M; Kasugai S; Ohya K; Miyamoto K
    Cancer Res; 1999 Mar; 59(6):1219-24. PubMed ID: 10096551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of dexamethasone and 1,25-Dihydroxyvitamin D on Walker carcinosarcoma 256 growth and parathyroid hormone-related protein secretion.
    Schilling T; Ziegler R; Raue F
    Horm Metab Res; 1996 Apr; 28(4):209-10. PubMed ID: 8740201
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective deficiency of 1,25-dihydroxycholecalciferol. A cause of isolated skeletal resistance to parathyroid hormone.
    Metz SA; Baylink DJ; Hughes MR; Haussler MR; Robertson RP
    N Engl J Med; 1977 Nov; 297(20):1084-90. PubMed ID: 198661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production.
    Waki Y; Miyamoto K; Kasugai S; Ohya K
    Jpn J Cancer Res; 1995 May; 86(5):470-6. PubMed ID: 7540609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of resistance to the phosphaturic effect of the parathyroid hormone in the hamster.
    Knox FG; Preiss J; Kim JK; Dousa TP
    J Clin Invest; 1977 Apr; 59(4):675-83. PubMed ID: 14974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory aids in the diagnosis of metabolic bone disease.
    Goldsmith RS
    Orthop Clin North Am; 1972 Nov; 3(3):545-60. PubMed ID: 4344932
    [No Abstract]   [Full Text] [Related]  

  • 19. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
    Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
    Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.